Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

NCT02181634 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT02181634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02181634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Completed
Start date
December 9, 2014
Completion date
October 1, 2017
Enrollment
74 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma